Sotera Health (NASDAQ:SHC – Get Free Report) and Repligen (NASDAQ:RGEN – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, risk, dividends and valuation.
Analyst Ratings
This is a summary of current ratings for Sotera Health and Repligen, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sotera Health | 1 | 2 | 7 | 0 | 2.60 |
| Repligen | 1 | 3 | 12 | 2 | 2.83 |
Sotera Health currently has a consensus price target of $21.14, indicating a potential upside of 27.29%. Repligen has a consensus price target of $178.57, indicating a potential upside of 6.43%. Given Sotera Health’s higher possible upside, equities analysts plainly believe Sotera Health is more favorable than Repligen.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sotera Health | $1.16 billion | 4.08 | $77.94 million | $0.60 | 27.68 |
| Repligen | $738.26 million | 14.53 | $48.89 million | ($0.21) | -799.00 |
Sotera Health has higher revenue and earnings than Repligen. Repligen is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
91.0% of Sotera Health shares are held by institutional investors. Comparatively, 97.6% of Repligen shares are held by institutional investors. 15.4% of Sotera Health shares are held by insiders. Comparatively, 0.6% of Repligen shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Sotera Health and Repligen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sotera Health | 14.11% | 38.46% | 7.66% |
| Repligen | -1.47% | 5.49% | 3.93% |
Risk and Volatility
Sotera Health has a beta of 1.94, meaning that its share price is 94% more volatile than the S&P 500. Comparatively, Repligen has a beta of 1.11, meaning that its share price is 11% more volatile than the S&P 500.
Summary
Sotera Health beats Repligen on 10 of the 15 factors compared between the two stocks.
About Sotera Health
Sotera Health Company is a global provider of sterilization, laboratory testing and advisory services for the medical device, pharmaceutical and food industries. Its services help customers assess product safety, meet regulatory requirements and prepare products for use. Through Sterigenics, the company provides contract sterilization using technologies including ethylene oxide, gamma irradiation and electron beam processing. Nelson Labs offers microbiological and analytical testing, as well as consulting, for medical devices and pharmaceutical products.
About Repligen
Repligen is a life sciences company that develops and supplies technologies used in the manufacture of biologic medicines. Its products support biopharmaceutical companies and contract manufacturers in producing treatments such as monoclonal antibodies, vaccines and gene therapies. The company’s offerings span several stages of bioprocessing, including filtration, chromatography, fluid management and process analytics. Its products include filtration systems and single-use components, chromatography solutions and instruments that help monitor and control manufacturing processes.
Receive News & Ratings for Sotera Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sotera Health and related companies with MarketBeat.com's FREE daily email newsletter.
